Becton Dickinson and (NYSE:BDX) received a $260.00 target price from analysts at Deutsche Bank in a report issued on Friday. The firm currently has a “buy” rating on the medical instruments supplier’s stock. Deutsche Bank’s target price would suggest a potential upside of 21.31% from the stock’s current price.
Other research analysts also recently issued research reports about the company. Zacks Investment Research raised Becton Dickinson and from a “hold” rating to a “buy” rating and set a $234.00 price target for the company in a research note on Tuesday, October 31st. Piper Jaffray Companies reiterated a “buy” rating and set a $213.00 price objective on shares of Becton Dickinson and in a research report on Tuesday, September 12th. Wells Fargo & Co assumed coverage on Becton Dickinson and in a research report on Friday, September 22nd. They set an “outperform” rating and a $225.00 price objective for the company. Argus lifted their price objective on Becton Dickinson and to $235.00 and gave the stock a “buy” rating in a research report on Thursday, December 14th. They noted that the move was a valuation call. Finally, Morgan Stanley lifted their price objective on Becton Dickinson and from $205.00 to $245.00 and gave the stock an “equal weight” rating in a research report on Friday, November 3rd. Four research analysts have rated the stock with a hold rating, twelve have issued a buy rating and one has assigned a strong buy rating to the company. Becton Dickinson and presently has a consensus rating of “Buy” and a consensus target price of $221.13.
Becton Dickinson and (NYSE:BDX) opened at $214.32 on Friday. The stock has a market capitalization of $49,854.91, a price-to-earnings ratio of 46.09, a PEG ratio of 1.70 and a beta of 1.07. The company has a debt-to-equity ratio of 1.44, a quick ratio of 5.03 and a current ratio of 5.58. Becton Dickinson and has a one year low of $161.50 and a one year high of $229.68.
A number of institutional investors have recently bought and sold shares of the stock. Westwood Holdings Group Inc. grew its holdings in Becton Dickinson and by 24.2% in the 2nd quarter. Westwood Holdings Group Inc. now owns 1,056,487 shares of the medical instruments supplier’s stock valued at $206,136,000 after buying an additional 205,721 shares during the period. Colony Group LLC grew its holdings in Becton Dickinson and by 2.1% in the 2nd quarter. Colony Group LLC now owns 11,889 shares of the medical instruments supplier’s stock valued at $2,320,000 after buying an additional 239 shares during the period. State Street Corp grew its holdings in Becton Dickinson and by 3.5% in the 2nd quarter. State Street Corp now owns 10,270,221 shares of the medical instruments supplier’s stock valued at $2,003,834,000 after buying an additional 342,873 shares during the period. Peapack Gladstone Financial Corp grew its holdings in Becton Dickinson and by 1.3% in the 2nd quarter. Peapack Gladstone Financial Corp now owns 36,472 shares of the medical instruments supplier’s stock valued at $7,116,000 after buying an additional 453 shares during the period. Finally, Bessemer Group Inc. grew its holdings in Becton Dickinson and by 1.4% in the 2nd quarter. Bessemer Group Inc. now owns 978,050 shares of the medical instruments supplier’s stock valued at $190,827,000 after buying an additional 13,263 shares during the period. Hedge funds and other institutional investors own 87.72% of the company’s stock.
WARNING: This report was reported by American Banking and Market News and is the sole property of of American Banking and Market News. If you are viewing this report on another domain, it was illegally copied and reposted in violation of US & international trademark & copyright legislation. The legal version of this report can be accessed at https://www.americanbankingnews.com/2017/12/29/becton-dickinson-and-bdx-pt-set-at-260-00-by-deutsche-bank.html.
About Becton Dickinson and
Becton, Dickinson and Company (BD) is a global medical technology company engaged in the development, manufacture and sale of a range of medical supplies, devices, laboratory equipment and diagnostic products. The Company operates through two segments: BD Medical and BD Life Sciences. The BD Medical segment produces an array of medical technologies and devices that are used to help improve healthcare delivery in a range of settings.
